9.97 +0.01 (0.10%)
After hours: 5:38PM EST
|Bid||9.92 x 800|
|Ask||9.93 x 1100|
|Day's Range||9.90 - 10.40|
|52 Week Range||5.04 - 24.20|
|Beta (3Y Monthly)||1.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||Sep. 26, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.25|
Rite Aid Corporation today announced the results and anticipated settlement of its previously announced cash tender offers to purchase up to $100 million aggregate principal amount of its outstanding 7.70% Senior Notes due 2027 and 6.875% Senior Notes due 2028 .
Walgreens Boots Alliance Inc has been exploring whether to go private following private equity interest in the U.S drug store chain, which has a market value of more than $55 billion, according to people familiar with the matter. In recent months, Walgreens has held preliminary discussions with some of the world's largest private equity firms about putting together what would be the biggest ever leveraged buyout, the sources said. Walgreens has tasked investment bank Evercore Partners Inc with exploring whether a deal can be put together, the sources said, cautioning that a deal is far from certain.
Rite Aid Corporation (RAD) (“Rite Aid” or the “Company”) today announced that it has increased the offer price and extended the early tender premium for its previously announced cash tender offers (the “Tender Offers”) to purchase up to $100 million aggregate principal amount of its outstanding 7.70% Senior Notes due 2027 (“2027 Notes”) and 6.875% Senior Notes due 2028 (the “2028 Notes” and together with the 2027 Notes, the “Notes”). Under the new terms of the Tender Offers, (i) the Total Consideration for each series of Notes has been increased to $667.50 in cash per $1,000 principal amount of Notes, as set forth in the table below, and (ii) the payment of the Early Tender Premium has been extended to 11:59 p.m., New York City time, on November 12, 2019. Accordingly, the Early Tender Time and the Expiration Time for the Tender Offers will now be the same.
Rite Aid Corporation (RAD) (“Rite Aid” or the “Company”) today announced that it has commenced cash tender offers (the “Tender Offers”) to purchase up to $100 million aggregate principal amount of its outstanding 7.70% Senior Notes due 2027 (“2027 Notes”) and 6.875% Senior Notes due 2028 (the “2028 Notes” and together with the 2027 Notes, the “Notes”). The Tender Offers support the Company’s objective to reduce its total indebtedness while managing its liquidity and interest expense.
Supermarket giant Kroger (KR) became the latest retailer to discontinue the sale of electronic cigarettes amid regulatory scrutiny.
This collaboration is in line with Walgreens' (WBA) commitment toward providing affordable and convenient healthcare facilities to residents of North Carolina.
“Jim is a seasoned healthcare executive with health innovation, corporate development, strategy and healthcare provider-payor operating experience,” said Heyward Donigan, chief executive officer, Rite Aid. “I’m excited to join Rite Aid at such an inflection point in the health and wellness industry,” said Peters.
Today, Rite Aid (RAD) announced the kick-off of the company’s annual Pharmacy Champions program, held throughout October during American Pharmacists Month. Pharmacy Champions was created to celebrate the outstanding service provided by Rite Aid’s pharmacy team throughout the year. Rite Aid customers have the opportunity to recognize any pharmacist, pharmacy technician or wellness ambassador who has gone above and beyond in delivering exceptional health-related care to their patients.
Rite Aid (RAD) delivered earnings and revenue surprises of 50.00% and -0.91%, respectively, for the quarter ended August 2019. Do the numbers hold clues to what lies ahead for the stock?
Although solid performance in men's category and better margins are likely to contribute to Stitch Fix's (SFIX) Q4 results, high costs remains a matter of concern.
Rite Aid (RAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rite Aid (RAD) gains from increased immunizations and clinical pharmacy services, which are likely to continue. Decline in prescription reimbursement rates is a headwind.